CLINICAL DATA PGxHEALTH DIVISION
Clinical Data: From Targeted Science to Better Healthcare.

Stock Information
CLDA - (NASDAQ)
$16.51   + 0.55
Sep 3, 2010
4:00 PM ET

Clinical Data: From Targeted Science to Better Healthcare.
About UsInvestorsContact Us
Print Print page    E-mail E-mail page
From Targeted Science to Better Healthcare™

Clinical Data is a global biotechnology company developing a rich pipeline of targeted therapeutics. Our late-stage compounds includes two unique products, vilazodone™, a first-in-class drug candidate for the treatment of depression, and Stedivaze™, a potential best-in-class cardiac stress agent. By virtue of each compound’s targeted effect they offer potential advantages over currently available treatments, and may provide tangible benefits for patients, healthcare professionals and payers.

The Company’s PGxHealth Division is leveraging its expertise in biomarker discovery and commercialization to guide the development of our drug pipeline. PGxHealth also leads the commercial and laboratory efforts supporting our FAMILION® family of genetic tests for inherited heart diseases.

Recent Releases

Aug 9, 2010
Clinical Data, Inc. Reports First Quarter Fiscal Year 2011 Operational and Financial Results

Jul 29, 2010
Clinical Data, Inc. to Present at Upcoming Investor Conferences

more »

Events

Aug 13, 2010
Clinical Data, Inc, to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference

Aug 5, 2010
Clinical Data, Inc, to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference

more »

Investors:


  Shareholder Tools